SCHEMBL13614200

SCHEMBL13614200

CC(=O)OCC1OC(n2cnc(C#N)n2)C(OC(C)=O)C1OC(C)=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ THRB P10828 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ GALR3 O60755 1/20 0.48
▸ CA1 P00915 10/20 0.47
▸ CA2 P00918 10/20 0.47
▸ CA9 Q16790 10/20 0.47
▸ CA12 O43570 8/20 0.47
▸ CA14 Q9ULX7 8/20 0.47
▸ TSHR P16473 1/20 0.45
▸ PRKCA P17252 1/20 0.43
▸ AKT1 P31749 1/20 0.43
▸ PTK2 Q05397 1/20 0.43
▸ PRKAB2 O43741 1/20 0.43
▸ PRKAG1 P54619 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1377520 1.00 LMNA (0.51) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL12892515 1.00 LMNA (0.51) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL15031303 1.00 LMNA (0.51) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL12154623 0.90 CD69 (0.44) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL12879162 0.90 LMNA (0.40) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL12150456 0.90 LMNA (0.40) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL28449032 0.84 LMNA (0.55) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL14036675 0.84 LMNA (0.34) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL16349578 0.84 OGA (0.36) LMNAALDH1A1THRBSMN1; SMN2HIF1A
SCHEMBL5566952 0.83 LMNA (0.52) LMNAALDH1A1THRBSMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638496-B2 Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-12-29 — — US disclosed
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE NT5C2, PNP, SLC29A1 LMNA 3406/4885ALDH1A1 1998/4885THRB 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback